The use of 95% CI or 90% CI for drug product development - a controversial issue?

Published

Journal Article

For review and approval of drug products, a 95% confidence interval approach for evaluation of new drugs is commonly used, while a 90% confidence interval approach is considered for assessment of generic drugs and biosimilar products. In the past decade, FDA has been challenged for adopting different standards (i.e., 5% type-I error rate for new drugs and 10% type-I error rate for generics/biosimilars) for regulatory submissions of drugs and biologics. This note intends to clarify the confusion by pointing out the fundamental differences between (i) the concepts of point hypotheses and interval hypotheses, and (ii) the concepts of interval hypotheses testing and confidence interval approach. In general, the method of interval hypotheses testing is not equivalent to the confidence interval approach although they may be operationally equivalent under certain conditions.

Full Text

Duke Authors

Cited Authors

  • Chow, S-C; Zheng, J

Published Date

  • 2019

Published In

Volume / Issue

  • 29 / 5

Start / End Page

  • 834 - 844

PubMed ID

  • 31454298

Pubmed Central ID

  • 31454298

Electronic International Standard Serial Number (EISSN)

  • 1520-5711

Digital Object Identifier (DOI)

  • 10.1080/10543406.2019.1657141

Language

  • eng

Conference Location

  • England